Nico Gagelmann: iMTSS to Dissect the Drivers of Post-Transplant Outcomes
Nico Gagelmann, Physician at University Medical Center Hamburg-Eppendorf, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Transplantation and Cellular Therapy, adding:
“What does overall survival actually tell us about why a patient is at risk?
In the largest genomically annotated myelofibrosis transplant cohort to date (n=1,550), we developed and validated iMTSS to dissect the drivers of post-transplant outcomes.
The aim is to move beyond estimating survival toward understanding what drives an individual patient’s risk. To improve understanding and future study designs.
Key findings:
- Relapse was primarily driven by disease biology: particularly TP53 allelic state, alongside RAS pathway mutations, ASXL1, driver genotype, blasts, and blood counts.
- Non-relapse mortality was driven by a distinct set of patient and transplant factors, including performance status, donor type, age, and portal vein thrombosis.
- These two risk dimensions were nearly independent.
- Integrating both dimensions, iMTSS outperformed established disease- and transplant-specific prognostic systems for overall survival.”
Title: iMTSS: an integrated framework for biology- and patient-driven prognosis in myelofibrosis undergoing transplantation
Authors: Nico Gagelmann, Rachel B. Salit, Thomas Schroeder, Patrizia Chiusolo, Maria Chiara Finazzi, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Alessandro Vannucchi, Paola Guglielmelli, Chiara Nozzoli, Nils Leimkühler, Emanuele Angelucci, Massimiliano Gambella, Alessandro Rambaldi, Hans Christian Reinhardt, Andrea Bacigalupo, Bart L. Scott, Florian H. Heidel, Uday Popat, Nicolaus Kröger
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 15:10Ashenafi Tazebew Amare: Building the Future of Blood and Specialized Healthcare
-
Sep 20, 2026, 15:03Bastu Odoka: How Much Does Blood Transfusion Raise Hemoglobin in Children?
-
Sep 20, 2026, 14:58Julieta Rosales: Advancing Evidence-Based Stroke Care Through Education and Collaboration
-
Sep 20, 2026, 14:52Maha Othman: The Life, Function and Death of Platelets
-
Sep 20, 2026, 14:32Paul Cane: Antenatal Haemoglobinopathy Screening From Laboratory Testing to Family Care
-
Sep 20, 2026, 14:14New Insights Into Platelet Production in Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease